Why the study?
Anthracycline and anthraquinone agents cause cardiac dysfunction in childhood cancer, but evidence-based equivalence ratios for estimating risk are missing from international surveillance guidelines.
This guideline provides evidence-based equivalence ratios for daunorubicin (0.6) and mitoxantrone (10.5) compared to doxorubicin to better estimate the individual risk of cardiac dysfunction in childhood cancer survivors.
Answers are grounded in this paper and cite their sources.
May inform updated surveillance guidelines for childhood cancer survivors; leaves open precise ratios for epirubicin and idarubicin pending higher-quality data.
Anthracycline and anthraquinone agents are major contributors to cancer therapy-related cardiac dysfunction in childhood cancer. However, evidence-based equivalence ratios for estimating individual risk have not been incorporated into international surveillance guidelines. The International Late Effects of Childhood Cancer Guideline Harmonization Group systematically reviewed the literature on equivalence ratios for doxorubicin, daunorubicin, epirubicin, idarubicin, and mitoxantrone. Based on available evidence, benefit-harm considerations, and expert consensus, the panel concluded that the risk of cardiac dysfunction is lower with daunorubicin and higher with mitoxantrone compared with doxorubicin (moderate-quality evidence; strong recommendation). The panel recommends using an approximate ratio of 0.6 to convert daunorubicin to a doxorubicin-equivalent dose and a ratio of 10.5 for mitoxantrone (low-quality evidence; moderate recommendation). No recommendation was made for epirubicin or idarubicin due to inconclusive evidence.
No takes yet. Share an insight, caveat, or question.
Kouwenberg et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: